|
|
MALT1 |
MALT1 paracaspase |
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- FCERI mediated NF-kB activation
- CLEC7A (Dectin-1) signaling
- CLEC7A/inflammasome pathway
|
|
|
|
|
MAP2K4 |
mitogen-activated protein kinase kinase 4 |
- Oxidative Stress Induced Senescence
- Oxidative Stress Induced Senescence
- FCERI mediated MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Uptake and function of anthrax toxins
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
|
|
|
|
|
MAP2K5 |
mitogen-activated protein kinase kinase 5 |
|
|
|
|
|
MAP3K7 |
mitogen-activated protein kinase kinase kinase 7 |
- Activation of NF-kappaB in B cells
- NOD1/2 Signaling Pathway
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- Ca2+ pathway
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- TNFR1-induced NF-kappa-B signaling pathway
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Interleukin-1 signaling
- IRAK2 mediated activation of TAK1 complex
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- Alpha-protein kinase 1 signaling pathway
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
|
|
|
|
|
MAP4 |
microtubule associated protein 4 |
|
- Paclitaxel
- Docetaxel
- Artenimol
|
|
|
|
MAP7 |
microtubule associated protein 7 |
|
|
|
|
|
MAP7D1 |
MAP7 domain containing 1 |
|
|
|
|
|
MAP7D3 |
MAP7 domain containing 3 |
|
|
|
|
|
MAPK14 |
mitogen-activated protein kinase 14 |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
- CD163 mediating an anti-inflammatory response
- Regulation of MITF-M-dependent genes involved in pigmentation
|
- Minocycline
- Dasatinib
- 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
- N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- Doramapimod
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- R-1487
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- SD-0006
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
- Fostamatinib
|
|
|
|
MAPKAP1 |
MAPK associated protein 1 |
- PIP3 activates AKT signaling
- CD28 dependent PI3K/Akt signaling
- VEGFR2 mediated vascular permeability
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
|
|
|
|
MAPRE2 |
microtubule associated protein RP/EB family member 2 |
|
|
|
|
|
MARCHF1 |
membrane associated ring-CH-type finger 1 |
|
|
|
|
|
MARCHF2 |
membrane associated ring-CH-type finger 2 |
|
|
|
|
|
MARCHF4 |
membrane associated ring-CH-type finger 4 |
|
|
|
|
|
MARCHF6 |
membrane associated ring-CH-type finger 6 |
- ER Quality Control Compartment (ERQC)
|
|
|
|
|
MARCHF7 |
membrane associated ring-CH-type finger 7 |
|
|
|
|
|
MARCHF8 |
membrane associated ring-CH-type finger 8 |
|
|
|
|
|
MAVS |
mitochondrial antiviral signaling protein |
- DDX58/IFIH1-mediated induction of interferon-alpha/beta
- Ovarian tumor domain proteases
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- Negative regulators of DDX58/IFIH1 signaling
- Negative regulators of DDX58/IFIH1 signaling
- SARS-CoV-1 activates/modulates innate immune responses
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Evasion by RSV of host interferon responses
- PKR-mediated signaling
|
|
|
|
|
MBNL1 |
muscleblind like splicing regulator 1 |
|
|
|
|
|
MBOAT7 |
membrane bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7 |
- Acyl chain remodelling of PI
|
|
|